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Summary. A newly diagnosed 5-month-old infant with cystic fibrosis (CF) developed signs and 
symptoms of increased intracranial pressure (ICP) within days of starting pancreatic enzyme 
replacement therapy. Symptoms promptly resolved on two occasions after stopping enzyme 
replacement. At 10 months of age, enzyme replacement was well tolerated. Pediatr Pulmonol. 
1995; 19:39&397. 0 1995 Wiley-Liss, Inc. 
Key words: Cystic fibrosis, intracranial pressure, pancreatic enzyme therapy. 
INTRODUCTION 
Asymptomatic elevations of intracranial pressure 
(ICP) and a bulging cranial fontanelle in children with 
cystic fibrosis (CF) have been attributed to vitamin A 
deficiency. They were described as a transient phe- 
nomenon following initiation of treatment for cystic fi- 
brosis and improvement of the poor nutritional 
It was also speculated that intracranial pressure elevations 
may be associated with severe respiratory distress,' and 
initiation of pancreatic enzyme replacement has been re- 
ported with asymptomatic bulging fontanelle." 
This report describes an infant with CF who developed 
symptomatic elevation of ICP within days of starting 
pancreatic replacement. Symptoms resolved on two oc- 
casions shortly after pancreatic enzymes were stopped. 
This case is of interest because the increase in intracranial 
pressure resulted in symptoms. 
CASE REPORT 
A 1-year-old Caucasian male was diagnosed as having 
cystic fibrosis at 5 months of age secondary to failure to 
thrive, pneumonia and a sweat chloride of 123 mEq/L. 
He was homozygous for the mutation AF508. He was a 
product of a normal pregnancy. He was delivered by 
normal spontaneous vaginal delivery. Birth weight was 
3.60 kg and length was 50 cm. Length and weight had 
dropped from the 50th percentile and 75th percentile, 
respectively for age at birth to the tenth percentile and 
fifth percentile for age at diagnosis. When the diagnosis 
was made, treatment was started and included pancreatic 
enzyme replacement with Pancreasem (McNeil Pharma- 
ceutical, Spring House, PA) in a dose of 700 IU/kg/feed 
(daily dose 4,200 IU/kg) and vitamin supplements. Two 
days after starting the above treatment, he began vomit- 
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ing, followed by development of a bulging fontanelle and 
irritability. He was afebrile. He was admitted to a local 
hospital. CT scan of the head was normal, aside from the 
bulging fontanelle. Lumbar puncture was negative, how- 
ever, the opening pressure was not measured. While in 
the hospital, the pancreatic supplements were stopped. 
The patient did well and the discharge diagnosis was 
increased intracranial pressure of unknown etiology. 
Pancreatic supplements were restarted prior to discharge. 
One day after discharge, he returned to the local hospital 
with the same symptoms, i.e., vomiting, bulging fon- 
tanelle, and irritability. CT of the head was repeated and 
was negative, as was an MRI. Lumbar puncture showed 
an opening pressure of 4 W 2  cm H,O and a closing 
pressure of 10 cm H,O. The remaining LP results were 
negative. The patient improved during the hospitaliza- 
tion, while off pancreatic enzyme replacement. He was 
discharged home with a diagnosis of increased intracra- 
nial pressure, secondary to pancreatic enzyme supple- 
ments. 
Pancreatic enzymes were withheld, and he was main- 
tained on Pregestamil, with an accelerated growth pat- 
tern. Pancreatic supplements were restarted at 10 months 
of age after baby food was started and pancreatic insuffi- 
ciency was apparent. He was placed on Pancrease@, at a 
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priately and he did not have respiratory distress at the 
time he developed a bulging fontanelle. 
The transient nature and rapidity of onset of signs and 
symptoms on both occasions suggest that pancreatic sup- 
plementation played a major role in the etiology of in- 
creased intracranial pressure, especially since pancreatic 
supplement was the only elimination from the treatment 
protocol after reoccurrence of symptoms. 
In conclusion, this case report suggests the association 
of increased intracranial pressure with pancreatic enzyme 
replacement in a newly diagnosed CF infant. 
dose of 400 1Ulkg/meal, with a total daily dose of 2,000 
IU/kg. Since that time he has had no signs or symptoms 
of increased ICP. 
DISCUSSION 
Transient asymptomatic increased intracranial pressure 
shortly after initiation of treatment for cystic fibrosis has 
been reported repeatedly. The infants improved clini- 
cally and showed spontaneous resolution of the bulging 
fontanelle within a few weeks without interruption of CF 
treatment. 
Our patient demonstrated significant signs and symp- 
toms of increased intracranial pressure within days of 
starting the pancreatic enzyme replacement. Although 
these signs and symptoms resolved within 2 to 4 days 
after discontinuing therapy, they recurred within 24 hr 
when the pancreatic enzymes were restarted. When the 
pancreatic insufficiency became obvious, the pancreatic 
enzyme supplementation (Pancrease@ was used in both 
occasions) was restarted with no adverse effects. 
The increased intracranial pressure in our patient was 
symptomatic and not self-limiting. To our knowledge, 
this has not been reported previously. The symptoms 
could be due to more severe CF disease, especially that 
the patient was found to be homozygous AF508, a muta- 
tion associated with severe pancreatic insufficiency. lo 
The mechanism of increased intracranial pressure in 
cystic fibrosis patients is complex and has been attributed 
to vitamin A deficiency,’,’ catch up brain g r o ~ t h , ~ - ~  and 
severe respiratory distress.’ All of these causes seem 
unlikely in this case. The patient lacked xerophthalmia, 
corneal ulceration, anemia, and he lacked pathologic 
findings by skeletal X-ray. Also, the increased intracra- 
nial pressure reoccurred with resumption of pancreatic 
supplementation. The patient continued to grow appro- 
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